Clinical trials: HER2-positive Advanced Solid Tumors
Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II
Study of Azacitidine and Durvalumab in Advanced Solid Tumors
This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumor activity of azacitidine in combination with durvalumab…
- Conditions
- Microsatellite Stable Colorectal Carcinoma, Platinum Resistant Epithelial Ovarian Cancer Type II, Estrogen Receptor Positive and HER2 Negative Breast Cancer
- Trial name
- METADUR (NCT02811497)
- Testing
- Azacitidine, Durvalumab
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University Health Network, Toronto